Jul 8, 2026 07:45AM
Jul 8, 2026 07:45AM
Jun 30, 2026 09:00AM
Jun 26, 2026 12:35PM
Jun 26, 2026 12:35PM
Jun 14, 2026 02:01PM
Jun 13, 2026 06:33AM New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple my
Jun 11, 2026 07:45AM
Jun 11, 2026 07:45AM
Jun 11, 2026 07:43AM
Jun 11, 2026 02:03AM
Jun 11, 2026 02:03AM
Jun 3, 2026 03:14AM
Jun 3, 2026 12:04AM Johnson & Johnson's nipocalimab meets primary endpoint in lupus trial
Jun 3, 2026 12:04AM
Jun 3, 2026 12:03AM
May 31, 2026 08:29AM
May 31, 2026 08:28AM
May 31, 2026 08:27AM
May 29, 2026 02:00PM
May 29, 2026 02:00PM RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
May 29, 2026 08:41AM
May 29, 2026 08:18AM
May 28, 2026 07:10PM
May 28, 2026 07:10PM
May 15, 2026 02:58PM
May 13, 2026 08:30AM
May 11, 2026 08:01AM Johnson & Johnson presents neuropsychiatry data at medical conferences
May 11, 2026 08:00AM
May 5, 2026 08:05AM
May 5, 2026 08:05AM
May 5, 2026 08:05AM
May 5, 2026 08:05AM
May 5, 2026 07:00AM
May 5, 2026 07:00AM Johnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
May 4, 2026 08:03AM
May 4, 2026 08:00AM
Apr 27, 2026 08:03AM
Apr 27, 2026 08:03AM
Apr 24, 2026 08:38AM
Apr 22, 2026 08:07AM
Apr 22, 2026 08:05AM IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
Apr 16, 2026 11:00AM
Apr 15, 2026 07:21AM
Apr 14, 2026 06:20AM
Apr 10, 2026 08:01AM
Apr 10, 2026 08:00AM
Apr 9, 2026 08:30AM
Apr 1, 2026 12:52PM Johnson & Johnson receives permanent billing code for bladder cancer treatment
Mar 30, 2026 04:21AM

325,594 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All